FIGO position statement on opportunistic salpingectomy as an ovarian cancer prevention strategy
- PMID: 39412638
- DOI: 10.1002/ijgo.15884
FIGO position statement on opportunistic salpingectomy as an ovarian cancer prevention strategy
Abstract
Epithelial ovarian cancer, with the highest mortality rate among gynecologic malignancies, often goes undetected until advanced stages due to non-specific symptoms. Traditional prevention strategies such as bilateral salpingo-oophorectomy (BSO) are limited to high-risk women and induce surgical menopause, often leading to significant health concerns. Recent findings suggest that many serous epithelial ovarian cancers originate in the fallopian tubes rather than the ovaries. This has led to the hypothesis that salpingectomy, with preservation of the ovaries, may reduce the risk of ovarian cancer while avoiding the adverse effects of early menopause. Studies show that bilateral salpingectomy (BS) significantly reduces ovarian cancer incidence even in average-risk women. Bilateral salpingectomy has been demonstrated to be safe with minimal added operative time, no adverse effects on ovarian function and is also cost effective. Opportunistic salpingectomy (OS), at the time of non-gynecologic surgeries, is a promising strategy for reducing ovarian cancer risk, especially among average-risk women who have completed childbearing. It offers a safe and cost-effective alternative to traditional methods. Emerging data supports incorporating OS into standard surgical practices for benign gynecologic conditions and considering it during unrelated abdominal/pelvic surgeries after adequate patient counseling and informed consent. Further training of non-gynecologic surgeons in OS is recommended to expand its preventive benefits.
Keywords: cancer prevention; opportunistic; salpingectomy.
© 2024 The Author(s). International Journal of Gynecology & Obstetrics published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics.
References
REFERENCES
-
- Siegel RL , Miller KD , Jemal A . Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7‐30. doi:10.3322/CAAC.21387
-
- Mathis J , Jellouli MA , Sabiani L , Fest J , Blache G , Mathevet P . Ovarian cancer screening in the general population. Horm Mol Biol Clin Invest. 2020;41(3):20190038 doi:10.1515/HMBCI-2019-0038/MACHINEREADABLECITATION/RIS
-
- Kotsopoulos J , Gronwald J , Karlan B , et al. Age‐specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2018;150(1):85‐91. doi:10.1016/J.YGYNO.2018.05.011
-
- Swanson CL , Bakkum‐Gamez JN . Options in prophylactic surgery to prevent ovarian cancer in high‐risk women: how new hypotheses of fallopian tube origin influence recommendations. Curr Treat Options Oncol. 2016;17(5):20. doi:10.1007/S11864-016-0396-2
-
- Jervis S , Song H , Lee A , et al. Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. J Med Genet. 2014;51(2):108‐113. doi:10.1136/JMEDGENET-2013-102015
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources